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Abstract
Objective: “Pain interference” and “headache impact” refer to negative consequences that pain and headache have on
one’s life. This study investigated determinants of these negative impacts in a large patient cohort who have chronic
migraine with medication overuse.
Methods: Six hundred and eleven adults were enrolled from 34 headache, neurology, and primary care clinics. Negative
consequences of chronic migraine with medication overuse were determined using the Patient-Reported Outcomes
Measurement Information System (PROMIS) Pain Interference 6b questionnaire and the Headache Impact Test 6.
Relationships between PROMIS-6b and Headache Impact Test 6 scores with demographics, headache characteristics,
medication use, anxiety symptoms, and depression symptoms were assessed with linear regression. Elastic Net regression was used to develop a multiple regression model.
Results: PROMIS-6b T-Scores averaged 65.2 (SD 5.4) and Headache Impact Test 6 scores averaged 65.0 (SD 5.3),
indicating severe negative consequences of chronic migraine with medication overuse. Chronic migraine with medication
overuse interfered with enjoyment of life, concentration, daily activities, doing tasks away from home, and socializing.
Depression symptom severity had the strongest relationship with pain interference and headache impact. Moderate-tosevere headache frequency, headache intensity, and anxiety symptoms were also associated with pain interference and
headache impact.
Conclusions: Chronic migraine with medication overuse is associated with substantial negative consequences, the
extent of which is most strongly related to depression symptoms.
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Introduction
Chronic migraine (CM), which has an estimated prevalence of about 2% in the general population, manifests with at least 3 months of headaches on at least 15
days per month, including at least 8 days per month
that meet International Classification of Headache
Disorders, 3rd edition (ICHD-3) criteria for migraine
with or without aura (1–3). Approximately half of
people with CM take symptomatic migraine medications with a high enough frequency that it is classified
as “medication overuse” (MO) (1,4). Those affected by
CM have multiple domains of their lives negatively
impacted, an impact that is even greater amongst
those who have CM with MO (5–7). The patient demographics, headache characteristics, medication use,
and psychological symptoms that impact the extent
to which CM with MO interferes with daily life, and
the relative importance of such factors, have been inadequately investigated.
The impact of CM with MO on daily life was measured in the Medication Overuse Treatment Strategy
(MOTS) trial, a randomized, pragmatic clinical trial
testing two treatment strategies for patients who have
CM with MO. Validated questionnaires were used to
measure “pain interference”, a term that describes the
consequences that pain of any kind has on different
aspects of a person’s life, as well as the impact of headache on daily life were measured (8). In the MOTS
trial, patients reported the impact that pain and headache caused on their day-to-day activities, doing tasks
away from home, social functioning, ability to concentrate, mood, and their enjoyment of life and recreational activities. The objective of this analysis was to
investigate pain interference and headache impact in
patients who have CM with MO and to determine
the demographics, headache characteristics, medication
use factors, and psychological symptoms that are most
strongly associated with pain interference severity.

Methods
Patient enrolment, eligibility, and consent
MOTS trial patients (n ¼ 611) were enrolled from 34
healthcare sites in the USA, including headache specialty, general neurology, and primary care clinics.

Men and women who were at least 21 years old and
had CM with MO according to ICHD-3 beta diagnostic criteria were eligible (9). Patients were willing to be
randomized to either of the two clinical trial treatment
strategies (migraine prevention medication with immediate switching from the overused medication to an
alternate acute therapy that can be used with a limited
frequency or migraine prevention medication without
immediate switching from the overused medication),
agreed to provide information in a daily headache
diary, and could not have had changes to their
migraine preventive therapy within four weeks of
enrolment. Potential participants were not offered
enrolment if there were safety concerns related to
either of the two treatment strategies, such as opioid
or barbiturate withdrawal syndrome if a patient was
randomized to immediate discontinuation of the overused medication.
All patients participated in an informed consent process and signed Institutional Review Board approved
consent documents. The MOTS trial was registered
with clinicaltrials.gov (https://clinicaltrials.gov/ct2/sh
ow/NCT02764320) prior to the enrolment of the first
patient.

Patient assessments
Guidance on data collection for headache studies provided by the National Institutes of Health (NIH)
National Institute of Neurological Disorders
(NINDS) common data elements (available at:
https://www.commondataelements.ninds.nih.gov/h
eadache), as well as patient reported outcomes from the
NIH Patient-Reported Outcomes Measurement
Information System (PROMIS), were used when developing MOTS methods. Assessments completed prior to
randomization, and that are included in this manuscript, included: demographics, headache characteristics, medication use, Generalized Anxiety Disorder 7
(GAD-7), Patient Health Questionnaire 9 (PHQ-9),
PROMIS Pain Interference 6b, and Headache Impact
Test 6 (HIT-6).
Using a structured interview, patients self-reported
their baseline headache frequency (i.e. average number
of days per month (30 days) with headache of any kind/
severity during the prior 3 months), frequency of moderate to severe intensity headaches (i.e. number of days

Schwedt et al.
during the prior 30 days during which headache
become moderate or severe intensity at any time), average headache intensity (i.e. on days with headache,
average headache intensity on a scale from 0 ¼ no
pain to 10 ¼ most severe pain), number of years with
migraine (calculated from patient report of the month
and year of their first migraine), number of years with
CM (calculated from patient report of the month and
year during which they first developed CM), number of
years with MO (determined by research team using
patient-reported data), and types and frequency of
medications used (determined by research team using
patient-reported data).
Symptoms of anxiety were assessed using the GAD7, a seven-question screening instrument for assessing
symptoms of anxiety during the prior 2 weeks (10).
Each question is scored from 0 (“not at all”) to 3
(“almost all the time”) and the sum of the answers
yields a total score from 0–21: 0–4 ¼ no anxiety,
5–9 ¼ mild anxiety, 10–14 ¼ moderate anxiety, and
15–21 ¼ severe anxiety.
Symptoms of depression during the prior 2 weeks
were assessed using the PHQ-9. Each question is
scored from 0 (“not at all”) to 3 (“nearly every day”)
and the sum of the answers yields a total score of 0 to
27 for depression severity: 0–4 ¼ minimal depression,
5–9 ¼ mild depression, 10–14 ¼ moderate depression,
15–19 ¼ moderately severe depression, and 20–
27 ¼ severe depression (11,12).
The PROMIS Pain Interference 6b questionnaire
assesses the extent to which pain interfered with a
patient’s enjoyment of life, ability to concentrate,
day-to-day activities, recreational activities, doing
tasks away from home (e.g. getting groceries, running
errands), and socializing with others during the prior 7
days (13). For all questions except socializing with
others, respondents choose one of five possible
responses to how much pain interfered (e.g. how
much did pain interfere with your enjoyment of life?):
“Not at all”, “a little bit”, “somewhat”, “quite a bit”,
or “very much”. For the question asking about how
often pain kept them from socializing with others,
respondents choose one of five possible responses:
“Never”, “rarely”, “sometimes”, “often”, or “always”.
Raw scores on a scale from 6 to 30 points are converted
into a standardized score, with a mean of 50 and a
standard deviation of 10 in the United States general
population. The PROMIS Pain Interference questionnaire has been tested and validated across numerous
pain conditions and in healthy individuals (8).
The HIT-6 is a six-item questionnaire that assesses
the impact headaches have on a person’s ability to
function on the job, at home, at school, and in social
situations (14). The HIT-6 also asks about the frequency of severe headaches and the frequency of wanting to
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lie down due to headache. Three of the questions refer
to the prior 4 weeks, while the other three questions do
not specify a time period. Each question has five
response options: “Never”, “rarely”, “sometimes”,
“very often”, and “always”. The answers are summed
to obtain a total score that ranges from 36 to 78, with
higher numbers indicating more impact from headache:
36–49 ¼ little or no impact, 50–55 ¼ some impact,
56–59 ¼ substantial impact, 60–78 ¼ severe impact.

Statistical Analyses
Descriptive statistics were used to characterize the
MOTS patients, their headache characteristics, medication use, symptoms of anxiety and depression, pain
interference, and headache impact.
The relationships between the PROMIS 6b T-score
and patient demographics (age, race, ethnicity, sex),
headache characteristics (number of headache days,
number of moderate to severe headache days, average
headache intensity, number of years with migraine,
number of years with CM), medication use (medication
class overused, overuse of one vs. multiple classes of
migraine medication, number of days using an abortive
medication, number of years in a MO pattern, use of
migraine preventive medication, use of non-medicinal
migraine therapies), anxiety symptoms (GAD-7 total
score), and depression symptoms (PHQ-9 total score)
were assessed by using linear regression. Relationships
of each of these variables with the HIT-6 score were
also assessed. Multivariable modeling was performed
for pain interference and headache impact in order to
determine which additional variables contributed to
pain interference and headache impact beyond that
already explained by an individual variable. All variables in Table 1 were potential candidates for inclusion
in each multivariable model. A subset of these variables
was selected by using linear regression with Elastic Net
regularization. The Elastic Net method prevents overfitting the sample by minimizing a penalty term along
with the model residuals. Elastic Net method was used
because it selects a subset of variables without entirely
ignoring variables that are somewhat correlated with
other variables.

Results
Patient enrolment and demographics
Patients were enrolled between February 20, 2017 and
June 16, 2020. Headache specialty clinics enrolled 412
(66%) of the patients, 159 (25%) patients were enrolled
from general neurology clinics, and 54 (9%) patients
were enrolled from primary care clinics. Baseline
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Table 1. Summary statistics, relationship with PROMIS 6b T-Score, and relationship with HIT-6 score. Mean (SD), N; or n/N (%).
PROMIS 6b T
Summary
PHQ-9 (0–27)
GAD-7 (0–21)
Moderate-severe
headache days (/30)
Average headache
intensity (0–10)
White non-hispanic
Simple analgesic
overuse
Headache days (/30)
Hispanic
Days using abortive
medications
(/month)
Combination medications overuse
Age (y)
Years with migraine
White
Ergotamine overuse
Years with medication
overuse
Female
Years with chronic
migraine
Opioid overuse
Multiple medications
overuse
Triptan overuse
Using non-medicinal
migraine therapy
Using preventive
migraine medication

R2

b

HIT-6
SE

p

R2

b

SE

p

8.9 (6.0), 610
7.8 (5.5), 609
13.7 (7.2), 611

0.24
0.14
0.09

0.441
0.365
0.222

0.032
0.037
0.029

<0.001
<0.001
<0.001

0.21
0.16
0.09

0.405
0.379
0.222

0.032
0.036
0.029

<0.001
<0.001
<0.001

6.3 (1.7), 611

0.06

0.81

0.12

<0.001

0.10

0.99

0.12

<0.001

0.01
0.01

1.24
1.15

0.50
0.45

0.01
0.01

0.02
0.01

1.70
1.02

0.49
0.44

0.001
0.02

0.040
0.63
0.035

0.01
0.03
0.03

0.00
0.01
0.00

0.039
0.62
0.034

0.12
0.06
0.26

456/611 (75%)
383/610 (63%)
24.2 (5.5), 611
86/601 (14%)
23.5 (6.3), 610

0.01
0.01
0.01

0.098
1.34
0.077

0.061
1.15
0.039

244/610 (40%)

0.01

0.88

0.45

0.049

0.00

0.25

0.44

0.57

45
23
492/604
6/610
4.9

(13), 611
(14), 607
(81%)
(1%)
(6.0), 610

0.01
0.01
0.00
0.00
0.00

0.033
0.032
0.88
2.7
0.040

0.017
0.016
0.57
2.2
0.037

0.05
0.04
0.12
0.23
0.28

0.05
0.02
0.01
0.00
0.01

0.088
0.054
0.142
2.9
0.081

0.016
0.015
0.44
2.2
0.036

<0.001
0.001
0.01
0.19
0.02

532/610 (87%)
12 (11), 607

0.00
0.00

0.74
0.021

0.66
0.020

0.27
0.29

0.01
0.00

1.34
0.017

0.64
0.019

0.04
0.37

25/610 (4%)
84/610 (14%)

0.00
0.00

1.0
0.58

1.1
0.64

0.36
0.36

0.00
0.00

0.0
0.49

1.1
0.62

0.97
0.44

131/610 (21%)
85/610 (14%)

0.00
0.00

0.43
0.30

0.54
0.64

0.42
0.64

0.00
0.00

0.13
0.94

0.52
0.62

0.80
0.13

278/610 (46%)

0.00

0.01

0.44

0.98

0.00

0.08

0.43

0.85

PHQ-9: Patient Health Questionnaire 9; GAD-7: Generalized Anxiety Disorder 7.

PROMIS 6b Pain Interference scores were provided by
611 (98%) of the patients.
Mean age was 45 (SD 13) years with a median of 44
and a range from 21–83 years (Table 1). Sex at birth
was female for 532 (87%), male for 78 (13%), and sex
data were missing for one patient. Race was reported as
White 492 (81%), Black 40 (7%), Asian 7 (1%),
American Indian or Alaskan Native 2 (0.3%), chose
not to answer 7 (1%), and other race 63 (10%).
Hispanic ethnicity was reported by 86 of 601 (14%).
Race-ethnicity was categorized into a group other than
White-non-Hispanic for 25% of the total sample.

Headache characteristics
Mean number of headache days per 30 days was 24.2
(SD 5.5), including 13.7 (SD 7.2) days on which there
was moderate to severe headache intensity. Mean

headache intensity was 6.3 (SD 1.7) on a scale ranging
from 0 ¼ no pain to 10 ¼ most severe pain imaginable.
On average, patients had migraine for 23 (SD 14) years
and CM for 12 (SD 11) years.

Headache medication
Patients reported using symptomatic medication that
could be used to treat a headache on an average of
23.5 (SD 6.3) days per 30 days. They had been in an
MO pattern for an average of 4.9 (SD 6.0) years. The
overused medications were from the following pharmacologic classes: Simple analgesics ¼ 383 (63% of
patients), combination analgesics (not containing
opioids) ¼ 244 (40%), triptans ¼ 131 (21%), multiple
classes not individually overused ¼ 84 (14%),
opioids ¼ 25 (4%), and ergotamines ¼ 6 (1%). A
single medication class was overused by 69% of
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patients, while 31% overused medications from two or
more medication classes. At baseline, migraine preventive medication was being used by 278 (46% of
patients).

Anxiety and depression
The mean GAD-7 score was 7.8 (SD 5.5), suggestive of
“mild” anxiety symptoms. Scores were consistent with
“no” anxiety for 33%, 31% had symptoms suggestive
of “mild” anxiety, 22% had “moderate” anxiety, and
14% had severe anxiety. The mean PHQ-9 score was
8.9 (SD 6.0) suggestive of “mild” depression symptoms.
Scores were consistent with “no depression” for 27% of
patients, “mild” depression for 32%, “moderate”
depression for 22%, “moderately severe” depression
for 13%, and “severe” depression for 6%.

Pain interference
PROMIS 6b T-Scores ranged from 41 to 78 points,
with a mean of 65.2 points (SD 5.4). The mean score
was 1.5 standard deviations worse than the reference
population from the United States general population
(mean 50, SD 10), suggestive of substantial pain interference in this CM with MO population. The six items
contributed approximately equally to the total score.
The most frequent score was a “4” for all six items,
and the mean item score ranged from 3.4 to 3.7
among the six items (Table 2).
The PHQ-9 had the strongest relationship with
PROMIS 6b (Table 1). Each point higher on the
PHQ-9 was associated with 0.441 points higher on
the PROMIS 6b T-Score. Variation in PHQ-9 scores

accounted for 24% of the variation in PROMIS 6b
T-Score (Figure 1). The GAD-7 was also associated
with PROMIS 6b. Each point higher on the GAD-7
was associated with 0.365 points higher PROMIS 6b
T-Score, and variation in GAD-7 scores accounted for
14% of the variation in PROMIS 6b T-Score.
Relationships amongst the PHQ-9 total score and
the individual items on the PROMIS 6b were approximately equal for all six items (Table 2). The percentage
of variation explained by the PHQ-9 ranged from 15%
to 20% among the six items, and the slope of the relationship ranged from 0.06 to 0.07. A 10-point change in
PHQ-9 score corresponded to approximately 0.6 points
change on the individual items of the PROMIS 6b.
The headache characteristics with the strongest relationship with PROMIS 6b were the frequency of
moderate-to-severe headaches and the average headache intensity. Each additional day of moderate-tosevere headache per thirty days was associated with
0.222 points higher PROMIS 6b T-Score, and each
additional point of headache intensity accounted for
0.81 points higher PROMIS 6b T-Score.
No other characteristic accounted for more than 1%
of the variation in PROMIS 6b T-Score.
A multivariable score with terms for PHQ-9, moderate-to-severe headache frequency, and average headache intensity (57.09 þ 0.39 PHQ-9 þ 0.49 Intensity þ
0.12 Frequency) accounted for 29% of the variation
in PROMIS 6b T-Score (Figure 2).

Headache impact
HIT-6 scores ranged from 44 to 78, with a mean and
median of 65.0 (SD 5.3) indicating severe impact from

Table 2. Summary statistics for each item on the PROMIS 6b and HIT-6, and their relationships with PHQ-9 score. The table reports
the number of patients who responded to each question with an answer of 1 (“not at all “or “never”) to 5 (“very much” or “always”)
and the average response for the entire study cohort. Average responses were between 3 and 4, demonstrating substantial pain
interference and headache impact in each of the domains. Depression symptom severity, measured by the PHQ-9, was significantly
associated with pain interference and headache impact in every domain.

PROMIS 6b
Enjoyment of life
Concentration
Daily activity
Enjoyment of recreation
Doing tasks away from home
Socializing
HIT-6
Severe pain
Daily activity
Lie down
Too tired
Irritated
Concentration

1

2

3

4

5

Mean (SD)

R2

b

SE

p

11
11
16
16
23
14

52
53
65
63
78
65

165
171
205
163
196
232

274
271
236
240
227
262

109
105
89
129
87
38

3.68 (0.92)
3.66 (0.92)
3.52 (0.96)
3.7 (1.0)
3.5 (1.0)
3.40 (0.85)

0.15
0.20
0.17
0.18
0.16
0.19

0.059
0.068
0.066
0.070
0.067
0.061

0.006
0.006
0.006
0.006
0.006
0.005

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001

3
6
4
9
12
6

17
45
17
44
35
30

163
226
104
228
111
208

370
286
273
287
279
303

58
48
213
43
174
64

3.76
3.53
4.10
3.51
3.93
3.64

0.03
0.12
0.07
0.19
0.10
0.19

0.028
0.069
0.059
0.086
0.081
0.084

0.007
0.007
0.009
0.007
0.010
0.007

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001

(0.68)
(0.78)
(0.82)
(0.79)
(0.93)
(0.77)
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PROMIS 6b T-Score

80

70

60

50

40
0

10

20
PHQ-9

Figure 1. Relationship between PROMIS 6b and PHQ-9. Overlapping points were moved slightly in a random direction so that all
points are visible.

80

PROMIS 6b T-Score

70

60

50

40
60

65

70

75

Predicted PROMIS 6b T-Score

Figure 2. Relationship between PROMIS 6b and a multivariable predictor with terms for PHQ-9, frequency of moderate-to-severe
headaches, and average headache intensity.

headache. HIT-6 scores of at least 60 points were
reported for 562 (89%) of the patients. HIT-6 scores
were strongly correlated with PROMIS 6b T-Score
(Figure 3). One point difference on the HIT-6 was associated with 0.750 points on the PROMIS 6b T-Score (SE
0.028, p < 0.001). The HIT-6 scores accounted for 54%
of the variation in PROMIS 6b T-Scores (r ¼ 0.73).
Relationships with the HIT-6 were similar to those
for the PROMIS 6b (Table 1). Like the PROMIS 6b,

the PHQ-9 also had the strongest relationship with
HIT-6. (Figure 4) Each point higher on the PHQ-9
was associated with 0.405 points higher on the HIT6. Variation in PHQ-9 scores accounted for 21% of the
variation in HIT-6 scores. The GAD-7 was also associated with HIT-6. Each point higher on the GAD-7
was associated with 0.379 points higher HIT-6, and
variation in GAD-7 scores accounted for 16% of the
variation inn HIT-6 scores.
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PROMIS 6b T-Score

80

70

60

50

40
50

60

70

80

HIT-6
Figure 3. Relationship between PROMIS 6b and HIT-6. Overlapping points were moved slightly in a random direction so that all
points are visible.

80

HIT-6

70

60

50

0

10

20
PHQ-9

Figure 4. Relationship between HIT-6 and PHQ-9. Overlapping points were moved slightly in a random direction so that all points
are visible.

The percentage of variation explained by the PHQ-9
ranged from 3% to 19% among the individual items of
the HIT-6 (Table 2). The PHQ-9 had the strongest
relationships with the frequency of tiredness and difficulty concentrating, and the weakest relationship with
the frequency of severe pain.
Similar to PROMIS 6b, the headache characteristics
with the strongest relationship with HIT-6 were the
frequency of moderate-to-severe headaches and the

average headache intensity. Each additional day of
moderate-to-severe headache per 30 days was associated with 0.222 points higher HIT-6 score, and each additional point of headache intensity accounted for 0.10
points higher HIT score.
No other characteristic accounted for more than 5%
of the variation in HIT-6 score. A multivariable score
for HIT-6 also included terms for PHQ-9, moderate-tosevere headache frequency, and average headache

8

Cephalalgia 0(0)

HIT-6

70

60

50

60

65

70

Predicted HIT-6

Figure 5. Relationship between HIT-6 and a multivariable predictor with terms for PHQ-9, frequency of moderate-to-severe
headaches, average headache intensity, age, and GAD-7.

intensity. Age and GAD-7 also made slight contributions with relatively small coefficients. This multivariable model (57.47 þ 0.28 PHQ-9 þ 0.66 Intensity þ 0.13
Frequency – 0.075 Age þ 0.063 GAD-7) accounted for
33% of the variation in HIT-6 scores (Figure 5).

Discussion
The main findings of this analysis are that: a) CM with
MO is associated with substantial pain interference and
headache impact in multiple life domains; and b) the
extent of these negative consequences is associated with
symptoms of depression, symptoms of anxiety, frequency of days with moderate to severe headaches,
and average headache intensity. The results demonstrate the enormous impact that CM with MO has on
multiple aspects of one’s life, and that the severity of
that impact is related to specific headache characteristics and psychological symptoms.
“Pain interference” measures the extent to which
pain negatively impacts multiple different aspects of a
person’s daily activities. “Pain interference” is a highly
relevant health-related outcome in chronic pain disorders such as CM with MO. The PROMIS Pain
Interference questionnaire was developed based on
extensive review of the pain literature, existing published measures, expert clinical input, and qualitative
research with patients who have chronic pain conditions (13). The PROMIS Pain Interference questionnaire is a robust, standardized method for
quantifying the effects of chronic pain on patients’
lives and function, and the effects of treatment (13).

Several prior studies have demonstrated that migraine
is associated with disability and reduced quality of life,
often using the Migraine Disability Assessment
(MIDAS) questionnaire, HIT-6, Short-Form Health
Survey (SF-36), and Migraine Specific Quality of Life
questionnaires (7,15). Although disability and quality
of life are outcomes related to pain interference, there
are meaningful differences between the outcomes measured by these questionnaires with those measured by
the PROMIS Pain Interference 6b. Few studies have
specifically interrogated pain interference amongst
those with CM. A study of 667 adults with CM, 41%
of whom had MO, who were enrolled into a clinical
trial of erenumab had average baseline PROMIS Pain
Interference scores of 63.4, with significant posttreatment improvements compared to placebo (16,17).
Patients in the American Registry for Migraine
Research (ARMR), 67.2% of whom had CM, had an
average PROMIS pain interference score of 63.2 (18).
Participants in the MOTS trial, all of whom had CM
with MO, had baseline PROMIS Pain Interference
scores that were slightly higher than those in the
ARMR and erenumab studies. Furthermore, analysis
of the individual pain interference subdomains assessed
by PROMIS 6b demonstrated that CM with MO
impacts all measured aspects of life (enjoyment, concentration, daily activity, recreation, errands, socializing) substantially and largely equally.
Whereas the PROMIS Pain Interference questionnaire assesses the negative impacts from pain of any
kind, the HIT-6 specifically ascertains negative consequences from headache. Thus, the use of HIT-6 is
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complementary to the PROMIS Pain Interference
questionnaire. However, as anticipated, this analysis
demonstrated that PROMIS Pain Interference scores
are highly correlated with HIT-6 scores. Furthermore,
the headache and psychological characteristics that
explain variance in PROMIS Pain Interference scores
are similar to those that explain HIT-6 score variance.
Unlike the PROMIS Pain Interference questionnaire,
the HIT-6 has been used commonly in migraine studies,
including several studies of CM with MO (19–22). The
HIT-6 scores in the patients from the MOTS trial
reported herein, demonstrating severe headache
impact, are comparable to those reported in other studies of individuals who have CM with MO (19–22).
Depression symptoms were most strongly associated
with the extent of pain interference and headache
impact amongst those with CM with MO. Prior
migraine studies have demonstrated relationships
between depression with headache-related disability
and pain interference (18,23–27). Our findings expand
upon prior publications by demonstrating the relationship between depression symptoms with pain interference and headache impact specifically amongst a large
U.S. clinical patient population who have CM with
MO and by showing that depression symptoms
explained a larger amount of variance in pain interference and headache impact scores compared to patient
demographics, anxiety, headache characteristics, and
medication use factors. In addition, this analysis demonstrates that depression symptoms are associated with
each subdomain of the pain interference to a similar
extent, including concentration, socializing, enjoyment
of life, daily activities, enjoyment of recreation, and
doing tasks away from home. Depression symptoms
were also associated with each item of the HIT-6,
most strongly associated with difficulty concentrating
and tiredness.
In our study, anxiety symptoms were also associated
with pain interference and headache impact. Prior
migraine studies have found relationships between anxiety with poor quality of life and disability
(24,26,28,29). Like our study, the analysis of ARMR
data by Pearl and colleagues specifically investigated
the relationship between GAD-7 scores and PROMIS
Pain Interference scores (18). After controlling for age,
sex, headache frequency, years with migraine, and
average headache intensity, no relationship was found
between anxiety symptoms and pain interference.
However, only 67.2% of patients in ARMR had CM
(vs. 100% in this MOTS analysis) and the patients in
ARMR had less severe anxiety symptoms (ARMR
mean on GAD-7 ¼ 5.5 vs. MOTS mean on GAD7 ¼ 7.8), perhaps explaining the differences in study
results. Prior studies of the HIT-6 have found
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relationships between symptoms of anxiety and headache impact, including studies using the GAD-7
(10,26).
Average headache intensity and the number of days
with moderate to severe headache were associated with
pain interference and headache impact. Prior studies in
migraine have demonstrated the important relationship
of headache intensity with disability and pain interference (5,25,30–32). It seems intuitive that more severe
average headache intensity would be associated with
greater negative consequences from CM. The concept
of measuring average headache intensity is highly related to measuring the number of moderate-to-severe
headache days. Moderate-to-severe headache days are
a good indicator of days on which individuals have
ICHD-defined migraine attacks. It is expected that a
higher frequency of days with full-blown migraine
attacks would be associated with greater pain interference and headache impact.
It is notable that participant demographics, years
with migraine, years with CM, years with MO, the frequency and types of acute medications overused, and
the use of migraine-preventive medications did not significantly contribute to the variance in pain interference and headache impact scores. It could be
hypothesized that the overuse of certain migraine medications, like opiates, would be associated with greater
negative consequences. Although such a relationship
was not identified in this study, given the small
number of study patients overusing opiates, firm conclusions on this relationship cannot be drawn. It is
hoped that the use of effective migraine preventive
medication would be associated with less pain interference and headache impact. Reductions in headacherelated disability and improvements in quality of life
attributed to effective treatment have been demonstrated in numerous migraine prevention trials (15,33–35).
The lack of an association between the use of migraine
preventive therapy and negative consequences from
CM with MO in our study might be explained by the
preventive medication not being particularly effective,
an assumption supported by the fact that the patient
population consisted of individuals who had CM with
MO with high frequency severe headaches. The longitudinal component of the MOTS trial will allow for
analyses that investigate relationships between the use
of effective headache preventive therapy and reductions
in pain interference and headache impact among
patients who have CM with MO.
Although this analysis was cross-sectional and the
directionality of relationships can therefore not be
determined, results suggest the importance of managing psychological symptoms as well as headache frequency and intensity in patients who have CM with
MO. Presumably, a comprehensive therapeutic
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approach that reduces the frequency of migraine headaches, lessens the average intensity of recurrent headaches, and reduces symptoms of depression and
anxiety, would maximize reductions in pain interference and headache impact. This might be best accomplished through migraine-targeted preventive and
symptomatic therapies in combination with psychological interventions such as counseling, cognitive behavioral therapy, biofeedback, stress reduction techniques,
medications and other therapeutic interventions.
A limitation of this analysis is that much of the baseline data, such as headache frequency and intensity,
and number of years with CM and MO, were ascertained during a structured interview that relied on
patient recall. Another limitation is that the PROMIS
Pain Interference 6b questionnaire asks about the
impact of “pain”, as opposed to asking specifically
about the impact of “headache” or “migraine”. Since
individuals who have CM with MO often have comorbid non-headache related pain in addition to migraine,
the pain interference in this cohort likely reflects that
caused by migraine and other types of pain that might
all contribute to MO. Data on other pain conditions
were not available for these analyses. However, the
analyses also included the HIT-6 as a second outcome
measure, a questionnaire that specifically ascertains
negative impacts related to headache. Strong correlations between PROMIS Pain Interference scores and
HIT-6 scores and the high similarities between the
models that explained variance in PROMIS Pain
Interference scores and variance in HIT-6 scores suggest that both questionnaires are useful for studying
negative impacts of CM with MO. A minority of the
variance in PROMIS Pain Interference scores and
HIT-6 scores was explained by the models that included variables such as depression, anxiety, frequency of
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moderate to severe headache days, and average headache intensity. This indicates that there are factors not
included in our modeling that explain a substantial
amount of the variance in pain interference and headache impact We hypothesize that these other factors
might include non-migraine pain, cephalalgiaphobia
(i.e. fear of the next headache), medication side effects,
sleep quality, pain acceptance, pain catastrophizing,
and others (32,36). Future studies need to collect data
that measure these other factors and determine the
extent to which they might associate with pain interference and headache impact. Finally, since this is a crosssectional analysis, the direction of the relationships
between CM with MO, pain interference, headache
impact, depression, and anxiety cannot be proven.
One condition could cause another unidirectionally,
or there could be a bidirectional relationship, and
other unmeasured factors might mediate the
relationship.

Conclusions
Patients in the USA who have CM with MO have substantial pain interference and headache impact in multiple life domains, including enjoyment of life and
recreational activities, ability to concentrate, daily
activities, doing tasks away from home, and socializing.
The extent of these negative consequences can be partially explained by symptoms of depression and anxiety, average headache intensity, and the frequency of
days with moderate-to-severe headache. It is likely that
a comprehensive patient management approach that
targets headache and psychological symptoms would
optimally limit the impact that CM with MO has on
a person’s life.

Key findings
• Patients who have chronic migraine with medication overuse have substantial pain interference and headache impact in multiple life domains.
• The extent of pain interference and headache impact is most strongly associated with symptoms of depression. It is also associated with symptoms of anxiety, average headache intensity, and the frequency of
moderate to severe headaches.
• Results suggest that a comprehensive patient management approach that targets headache and psychological symptoms would optimally limit the impact that CM with MO has on a person’s life.
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